Efficace Fabio, Cannella Laura, Capodanno Isabella, Sancetta Rosaria, Porcu Veronica, Lunghi Monia, Biagi Annalisa, Castagnetti Fausto, Caocci Giovanni, Baldi Thomas, Marasca Roberto, Bonifacio Massimiliano, Gozzini Antonella, Martino Bruno, Sora Federica, Westerweel Peter E, Fazi Paola, Vignetti Marco, Pane Fabrizio, Breccia Massimo
Italian Group for Adult Hematologic Diseases (GIMEMA), Data Center and Health Outcomes Research Unit, Rome, Italy.
Hematology Unit, Azienda Unità Sanitaria Locale-IRCCS, Reggio Emilia, Italy.
Front Oncol. 2025 Aug 27;15:1645217. doi: 10.3389/fonc.2025.1645217. eCollection 2025.
We aimed to explore the prognostic value of patient-reported health-related quality of life (HRQoL) data for the achievement of early molecular response (EMR) at 3 months in patients with chronic phase chronic myeloid leukemia (CP-CML). We analyzed HRQoL baseline data of 436 newly diagnosed patients with CML patients enrolled in the GIMEMA Sustrenim trial. HRQoL was assessed by the EORTC QLQ-30 and the QLQ-CML24 questionnaires. In the multivariate analysis, the following factors were found to be independently associated with achievement of EMR: Sokal risk (low vs intermediate risk p=0.046 and low vs high risk p<0.001), nilotinib treatment (p<0.001) and higher patient-reported role functioning (EORTC QLQ-C30) (p<0.001). Current findings suggest the importance of assessing HRQoL at diagnostic workup of patients with CML as it may provide valuable prognostic information.
我们旨在探讨患者报告的健康相关生活质量（HRQoL）数据对慢性期慢性髓性白血病（CP-CML）患者3个月时实现早期分子反应（EMR）的预后价值。我们分析了参加GIMEMA Sustrenim试验的436例新诊断CML患者的HRQoL基线数据。通过欧洲癌症研究与治疗组织QLQ-30问卷和QLQ-CML24问卷评估HRQoL。在多变量分析中，发现以下因素与实现EMR独立相关：索卡尔风险（低风险与中风险p = 0.046，低风险与高风险p<0.001）、尼洛替尼治疗（p<0.001）以及患者报告的更高角色功能（欧洲癌症研究与治疗组织QLQ-C30）（p<0.001）。目前的研究结果表明，在CML患者诊断检查时评估HRQoL很重要，因为它可能提供有价值的预后信息。
